If You Invested in Curative Biotechnology Inc (CUBT)

Curative Biotechnology, Inc. (OTC: CUBT) is a development-stage biomedical company in the healthcare sector, focused on the biotechnology industry. According to the company’s public statements, Curative Biotech concentrates on novel therapies for rare diseases and is engaged in identifying, acquiring, and developing disease‑modifying therapeutic drug candidates with an emphasis on rare disease indications.

Business focus and therapeutic areas

Curative Biotech reports that it has ongoing programs in three main therapeutic areas: degenerative eye disease, infectious disease, and neuro‑oncology. Across these areas, the company describes itself as development stage, meaning its programs are focused on research, preclinical work, and early clinical development rather than commercialized products.

The company has highlighted a pipeline that includes three named programs:

• Metformin Reformulation – a metformin‑based ophthalmic formulation intended as an eye drop for the treatment of intermediate and late‑stage Age‑Related Macular Degeneration (AMD), including intermediate Dry AMD and Geographic Atrophy (GA) resulting from AMD.
• IMT504 – described as a novel immune therapy to treat rabies and as an adjuvant for vaccines.
• CURB906 – described as a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site with the stated aim of inhibiting tumor growth and migration.

Degenerative eye disease platform

In multiple disclosures, Curative Biotech states that it is concentrating its energy and resources on its degenerative eye disease platform. This platform is based on a worldwide exclusive license from the National Eye Institute (NEI) at the National Institutes of Health (NIH). The first therapeutic candidate on this platform is a metformin‑based reformulation designed for topical ophthalmic administration.

The company reports that this metformin eye drop is being developed for intermediate and late‑stage AMD, including Dry AMD and GA. Curative Biotech has disclosed completion of an Investigational New Drug (IND)‑enabling tolerance and toxicology study of metformin HCL solution by topical instillation in rabbits. It has also announced that the first‑in‑human clinical trial is planned to be conducted under a Cooperative Research and Development Agreement (CRADA) with the NEI.

Curative Biotech has further reported the filing of a Patent Cooperation Treaty (PCT) application titled “Ophthalmic formulation capable of delivering metformin to choroid RPE and retina,” indicating its focus on intellectual property around metformin‑based ophthalmic formulations.

Expansion into veterinary ophthalmology

In a later strategic update, the company described an intention to extend its metformin‑based eye drop program beyond human degenerative eye disease into canine (K9) ophthalmic indications. Curative Biotech specifically mentioned Progressive Retinal Atrophy (PRA) and Central Progressive Retinal Atrophy (CPRA) as target diseases. CPRA is described by the company as a K9 disease that closely mimics human Dry AMD and as eligible for the Minor Uses in Major Species accelerated approval pathway at the FDA’s Center for Veterinary Medicine (CVM.

According to the company, it intends to pursue CPRA as the first K9 indication in parallel with human Dry AMD, followed by PRA. The company’s disclosures also reference the veterinary ophthalmic drug market and characterize CPRA and PRA as unmet medical needs, while noting that there is no assurance that the CVM will accept its Dry AMD preclinical research as establishing reasonable expectation of efficacy.

Infectious disease and neuro‑oncology programs

Alongside its eye disease platform, Curative Biotech has repeatedly described additional programs:

• IMT504 (infectious disease) – presented as a novel immune therapy to treat rabies and as an adjuvant for vaccines.
• CURB906 (neuro‑oncology) – described as a fully humanized CD56 monoclonal antibody drug conjugate designed to deliver a cytotoxic payload directly to tumor cells, with the stated goal of inhibiting tumor growth and migration.

These programs are part of the company’s broader rare‑disease and oncology development efforts as described in its press releases.

Corporate developments and geographic footprint

Curative Biotech’s shares trade on the OTC market under the symbol CUBT. The company has issued multiple announcements regarding its capital markets plans, including an earlier intent to pursue a reverse stock split and an underwritten public offering, and more recently a decision to withdraw a previously planned S‑1 registration statement and adjust the proposed reverse split ratio. The company has also discussed plans to apply for an OTCQB Venture Market uplisting, while noting that there can be no assurance of acceptance.

The company has also announced the establishment of a Japanese subsidiary, Curative Biotech Japan K.K., formed to facilitate licensing transactions and asset acquisitions in Japan. Public statements describe this subsidiary as a vehicle to expand the company’s reach and presence in the Japanese market.

Strategic partnerships and advisory relationships

Curative Biotech has disclosed several relationships intended to support its development and financing activities. These include:

• An exclusive worldwide license from the National Eye Institute at the NIH for its degenerative eye disease platform.
• A CRADA with the NEI under which the first‑in‑human metformin eye drop trial is expected to be conducted.
• The engagement of Golden Eagle Capital Advisors, Inc. (GECA) as exclusive agent and strategic advisor, described by the company as a financial advisory group.
• A stated plan to seek a manufacturing and/or full product development sublicense agreement for its metformin‑based eye drops, with the goal of de‑risking operational execution, securing non‑dilutive funding via upfront and milestone payments, and accelerating potential commercialization.

Governance and scientific expertise

Curative Biotech has reported several board‑level appointments intended to strengthen its clinical and industry expertise. The company has announced the nomination or appointment of independent directors with backgrounds in ophthalmology, gene therapy, glaucoma, and biotechnology company building, and has referenced the creation of a Clinical Development Committee of the Board. These disclosures emphasize experience in ophthalmic drug development, regulatory submissions, and commercialization, aligned with the company’s focus on degenerative eye disease.

Development stage and risk considerations

Across its public communications, Curative Biotech consistently describes itself as a development‑stage biomedical company. Its programs, including the metformin eye drop, IMT504, and CURB906, are characterized as therapeutic candidates and pipeline assets rather than approved products. The company frequently notes that various plans, including clinical timelines, regulatory pathways, licensing negotiations, reverse stock splits, and uplisting efforts, are subject to uncertainty and may not proceed as expected.

How Curative Biotech fits within biotechnology and healthcare

Within the broader biotechnology and healthcare landscape, Curative Biotech positions itself, based on its disclosures, as a rare‑disease focused developer working in ophthalmology, infectious disease, and neuro‑oncology. Its emphasis on a licensed degenerative eye disease platform, metformin‑based ophthalmic formulations, and early‑stage immune and antibody‑drug conjugate programs reflects a research‑driven, development‑oriented business model rather than a commercial pharmaceutical operation.

Frequently asked questions about Curative Biotechnology, Inc.

The following FAQs summarize key points drawn directly from the company’s public statements.